CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>   <script> var _paq = window._paq = window._paq || []; /* tracker methods like "setCustomDimension" should be called before "trackPageView" */ _paq.push(['trackPageView']); _paq.push(['enableLinkTracking']); (function() { var u="//matomo.waset.org/"; _paq.push(['setTrackerUrl', u+'matomo.php']); _paq.push(['setSiteId', '2']); var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src=u+'matomo.js'; s.parentNode.insertBefore(g,s); })(); </script>  <title>Search results for: pamidronate</title> <meta name="description" content="Search results for: pamidronate"> <meta name="keywords" content="pamidronate"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="pamidronate" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2025/2026/2027">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="pamidronate"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 6</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: pamidronate</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6</span> Target Drug Delivery of Pamidronate Nanoparticles for Enhancing Osteoblastic Activity in Osteoporosis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Purnima%20Rawat">Purnima Rawat</a>, <a href="https://publications.waset.org/abstracts/search?q=Divya%20Vohora"> Divya Vohora</a>, <a href="https://publications.waset.org/abstracts/search?q=Sarika%20Gupta"> Sarika Gupta</a>, <a href="https://publications.waset.org/abstracts/search?q=Farhan%20J.%20Ahmad"> Farhan J. Ahmad</a>, <a href="https://publications.waset.org/abstracts/search?q=Sushama%20Talegaonkar"> Sushama Talegaonkar </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Nanoparticles (NPs) that target bone tissue were developed using PLGA–mPEG (poly(lactic-co-glycolic-acid)–polyethylene glycol) diblock copolymers by using pamidronate as a bone-targeting moieties. These NPs are expected to enable the transport of hydrophilic drugs. The NP was prepared by in situ polymerization method, and their in- vitro characteristics were evaluated using dynamic light scattering, transmission electron microscopy (TEM) and in phosphate-buffered solution. The bone targeting potential of the NP was also evaluated on in-vitro pre-osteoblast MCT3E1 cell line using ALP activity, degree of mineralization and RT-PCR assay. The average particle size of the NP was 101.6 ± 3.7nm, zeta potential values were negative (-25±0.34mV) of the formulations and the entrapment efficiency was 93± 3.1 % obtained. The moiety of the PLGA–mPEG–pamidronate NPs exhibited the best apatite mineral binding ability in-vitro MCT3E1 pre-osteoblast cell line. Our results suggested that the developed nanoparticles may use as a delivery system for Pamidronate in bone repair and regeneration, warranting further evaluation of the treatment of bone disease. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nanoparticle" title="nanoparticle">nanoparticle</a>, <a href="https://publications.waset.org/abstracts/search?q=pamidronate" title=" pamidronate"> pamidronate</a>, <a href="https://publications.waset.org/abstracts/search?q=in-situ%20polymerization" title=" in-situ polymerization"> in-situ polymerization</a>, <a href="https://publications.waset.org/abstracts/search?q=osteoblast" title=" osteoblast"> osteoblast</a> </p> <a href="https://publications.waset.org/abstracts/25173/target-drug-delivery-of-pamidronate-nanoparticles-for-enhancing-osteoblastic-activity-in-osteoporosis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/25173.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">485</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5</span> Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Piamsiri%20Sawaisorn">Piamsiri Sawaisorn</a>, <a href="https://publications.waset.org/abstracts/search?q=Tienrat%20%20Tangchaikeeree"> Tienrat Tangchaikeeree</a>, <a href="https://publications.waset.org/abstracts/search?q=Waraporn%20Chan-On"> Waraporn Chan-On</a>, <a href="https://publications.waset.org/abstracts/search?q=Chaniya%20Leepiyasakulchai"> Chaniya Leepiyasakulchai</a>, <a href="https://publications.waset.org/abstracts/search?q=Rachanee%20Udomsangpetch"> Rachanee Udomsangpetch</a>, <a href="https://publications.waset.org/abstracts/search?q=Suradej%20Hongeng"> Suradej Hongeng</a>, <a href="https://publications.waset.org/abstracts/search?q=Kulachart%20Jangpatarapongsa"> Kulachart Jangpatarapongsa</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Human Vγ9Vδ2 T lymphocytes are regarded as promising effector cells for cancer immunotherapy since they have the ability to eliminate several tumor cells through non-peptide antigen recognition and non-major histocompatibility complex (MHC) restriction. An issue of recent interest is the capability to activate γδ T cells by use of a group of drugs, such as pamidronate, that cause accumulation of phosphoantigen which is recognized by γδ T cell receptors. Moreover, their antigen presenting cell-like phenotype and function have been confirmed in many clinical trials. In this study, Vγ9Vδ2 T cells derived from normal peripheral blood mononuclear cells were activated with pamidronate and the expanded Vγ9Vδ2 T cells can recognize and kill chronic myeloid leukemia (CML) cells treated with pamidronate through their cytotoxic activity. To support the strong role played by Vγ9Vδ2 T cells against cancer, we provide the evidence that Vγ9Vδ2 T cells activated with CML cell lysate antigen can efficiently express antigen presenting cell (APC) phenotype and function. In conclusion, pamidronate can be used in intentional activation of human Vγ9Vδ2 T cells and can increase the susceptibility of CML cells to cytotoxicity of Vγ9Vδ2 T cells. The activated Vγ9Vδ2 T cells by cancer cells lysate can show their APC characteristics, and so greatly increase the interest in exploring their therapeutic potential in hematologic malignancy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=%CE%B3%CE%B4%20T%20lymphocytes" title="γδ T lymphocytes">γδ T lymphocytes</a>, <a href="https://publications.waset.org/abstracts/search?q=antigen-presenting%20cells" title=" antigen-presenting cells"> antigen-presenting cells</a>, <a href="https://publications.waset.org/abstracts/search?q=chronic%20myeloid%20leukemia" title=" chronic myeloid leukemia"> chronic myeloid leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=immunotherapy" title=" immunotherapy"> immunotherapy</a> </p> <a href="https://publications.waset.org/abstracts/103440/antigen-presenting-cell-characteristics-of-human-ghd-t-lymphocytes-in-chronic-myeloid-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/103440.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">192</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4</span> Assessment of the Concentration of Osteoprotegerin and Receptor Activator of Nuclear Factor κB Ligand in Children with Osteogenesis imperfecta Treated and Untreated with Bisphosphonates</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Paulina%20Adamiecka">Paulina Adamiecka</a>, <a href="https://publications.waset.org/abstracts/search?q=Agnieszka%20Byrwa-Sztaba"> Agnieszka Byrwa-Sztaba</a>, <a href="https://publications.waset.org/abstracts/search?q=Danuta%20Chlebna-Sok%C3%B3%C5%82"> Danuta Chlebna-Sokół</a>, <a href="https://publications.waset.org/abstracts/search?q=Bogumi%C5%82a%20G%C3%B3rczewska"> Bogumiła Górczewska</a>, <a href="https://publications.waset.org/abstracts/search?q=El%C5%BCbieta%20Jakubowska-Pietkiewicz"> Elżbieta Jakubowska-Pietkiewicz</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Osteogenesis imperfecta (OI) is a genetic bone disorder characterized by a greatly increased risk of fragility fractures. Bisphosphonates (BPNs) are widely used in treating children with osteogenesis imperfecta. Although there is good evidence that they increase BMD (bone mineral density), the effects on fracture incidence are conflicting, Bisphosophonates induce a rapid dose-dependent decrease in bone resorption markers, making them a potentially good indicator for monitoring bone metabolism and antiresorptive therapy. Objective(s): The aim of the study was to assess the clinical utility of OPG, sRANKL and OPG/RANKL ratio in children with osteogenesis imperfecta (type I, III and IV), as well as to establish if these cytokines can be used as an indicator for monitoring changes in bone metabolism during antiresorptive therapy. Material and methods: RANKL, OPG, osteoprotegerin bioactivity index (OPG/RANKL ratio) and other bone turnover markers were quantified in serum and urine of 102 OI patients (41 females, mean age 5,7), 22 of which were receiving cyclic intravenous pamidronate, and 56 healthy control subjects. Serum OPG and sRANKL were measured with ELISA kits from Biomedica and compared between groups. Results: Serum osteoprotegerin concentrations were significantly increased both in untreated (median: 5.15 IQR: 4.10 – 6.30 vs. median: 4.30 IQR: 3.15 – 4.90)(p=0.0061) and in treated (median: 5.30 IQR: 4.30 – 6.60 vs. median: 4.30 IQR: 3.15 – 4.90)(p=0.0123) OI subjects with respect to controls. However, no statistically significant changes in the OPG/RANK/RANKL system were found during treatment with sodium pamidronate. The concentration of alkaline phosphatase, deoxypyridinoline and urinary phosphorus excretion were also significantly higher in untreated patients with OI.Conclusions: Increased OPG concentration indicates its protective role against excessive bone loss OPG and sRANKL are not a good indicator for monitoring changes in bone metabolism during antiresorptive therapy, The clinical utility of serum OPG and sRANKL measurements as markers in children with OI requires additional investigation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=child" title="child">child</a>, <a href="https://publications.waset.org/abstracts/search?q=osteogenesis%20imperfecta" title=" osteogenesis imperfecta"> osteogenesis imperfecta</a>, <a href="https://publications.waset.org/abstracts/search?q=osteoporosis" title=" osteoporosis"> osteoporosis</a>, <a href="https://publications.waset.org/abstracts/search?q=pamidronate" title=" pamidronate"> pamidronate</a> </p> <a href="https://publications.waset.org/abstracts/198999/assessment-of-the-concentration-of-osteoprotegerin-and-receptor-activator-of-nuclear-factor-kb-ligand-in-children-with-osteogenesis-imperfecta-treated-and-untreated-with-bisphosphonates" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/198999.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">0</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3</span> Vitamin D Intoxication with Hypercalcemia Due to Overuse of Supplement</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sara%20Ataei">Sara Ataei</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Bagher%20Oghazian"> Mohammad Bagher Oghazian</a>, <a href="https://publications.waset.org/abstracts/search?q=Mania%20Radfar"> Mania Radfar</a> </p> <p class="card-text"><strong>Abstract:</strong></p> We describe a patient with hypercalcemia associated with the injection of high doses vitamin D as supplement for a period of six months. A 76-year-old woman had been taking an intramuscular injection of vitamin D 300,000 IU every ten days for six months. She was hospitalized with symptoms of hypercalcemia: chronic constipation, unstable gait, a chronic generalized musculoskeletal pain and increased fatigue. On admission her 25 (OH) vitamin D and Calcium levels were 559 nmol/L and 13.85 mg/dL respectively, and Parathyroid Hormone (PTH) level was 7.1 pg/mL. Immediately she received diuresis therapy with saline and furosemide in conjunction with calcitonin and pamidronate. At discharge her serum calcium level was 11.5 mg/dL. To lower endogenous overproduction of calcitriol, prednisolone 20 mg/day for 10 days was administered at discharge time. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=vitamin%20D" title="vitamin D">vitamin D</a>, <a href="https://publications.waset.org/abstracts/search?q=hypercalcemia" title=" hypercalcemia"> hypercalcemia</a>, <a href="https://publications.waset.org/abstracts/search?q=vitamin%20D%20toxicity" title=" vitamin D toxicity"> vitamin D toxicity</a>, <a href="https://publications.waset.org/abstracts/search?q=parathyroid%20hormone" title=" parathyroid hormone"> parathyroid hormone</a> </p> <a href="https://publications.waset.org/abstracts/22662/vitamin-d-intoxication-with-hypercalcemia-due-to-overuse-of-supplement" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/22662.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">499</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2</span> Impact of Anthropometric Parameters and Course of Osteogenesis Imperfecta in Children on FGF23 Levels</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Agnieszka%20Byrwa-Sztaba">Agnieszka Byrwa-Sztaba</a>, <a href="https://publications.waset.org/abstracts/search?q=El%C5%BCbieta%20Jakubowska-Pietkiewicz"> Elżbieta Jakubowska-Pietkiewicz</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Osteogenesis imperfecta (OI) is a rare bone dysplasia that occurs with a frequency of 1/15000-20000 live births. It is characterized by increased susceptibility of bone fractures, skeletal deformities, low stature and low bone mass. It results in impaired production of type I collagen. About 90% of people with OI are heterozygotes for mutations in the COL1A1 and COL1A2 genes, with a dominant inheritance pattern or sporadic mutations. Fibroblast growth factor 23 (FGF23) is a protein involved in the regulation of phosphate and 1,25- dihydroxyvitamin D3 metabolism on a negative feedback basis. FGF23 is secreted by osteocytes in response to increased serum calcitriol and phosphorus. Aim of the study: The purpose of the study was to evaluate the concentration of FGF23 among children with osteogenesis imperfecta and the differences with reference values in a healthy population of children and adolescents. Then, to evaluate how the course of osteogenesis imperfecta, including type of disease, number of bone fractures and bone mineral density are related to FGF23 concentration. Material and methods: The study included 47 children aged 3 to 17 years with a diagnosis of osteogenesis imperfecta, confirmed by genetic tests. The patients were hospitalized at the Department from August 2019 to September 2020 and were treated with intravenous infusions of sodium pamidronate. The course of the disease was analyzed, including the number of bone fractures, clinical symptoms, anthropometric parameters, and bone densitometry was performed by dual X-ray absorptiometry (DXA) in Total Body Less Head (TBLH) and Spine options with Z-score evaluation. FGF23 concentration was determined by ELISA method. The study was prospective in nature. Results: The mean level of FGF23 in the study group of patients was 645.09 pg/ml and was within the reference values for the developmental age population. There was no significant correlation between FGF23 concentration and anthropometric measurements: body weight (p=0.267) and height (p=0.429), gender (p=0.291) or pubertal stage (p=0.223) in the study group of patients. FGF23 levels were not related to the number of fractures (p=0.749), the number of sodium pamidronate cycles administered (p=0.580), bone mineral density parameters (Z-score), the form of osteogenesis imperfecta (p=0.156) or the genetic test result (p=0.573). FGF23 levels decreases with age (r = -0.32, p = 0.030) and BMI (r = -0.34, p = 0.020). Conclusions: The level of FGF23 in patients with osteogenesis imperfecta is lower the older and having a higher BMI child. This index cannot be a diagnostic tool in this group of patients, no differences were found between the concentrations in patients with osteogenesis imperfecta and the developmental age population. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=osteogenesis%20imperfecta" title="osteogenesis imperfecta">osteogenesis imperfecta</a>, <a href="https://publications.waset.org/abstracts/search?q=FGF23" title=" FGF23"> FGF23</a>, <a href="https://publications.waset.org/abstracts/search?q=anthropometric%20parameters" title=" anthropometric parameters"> anthropometric parameters</a>, <a href="https://publications.waset.org/abstracts/search?q=children" title=" children"> children</a> </p> <a href="https://publications.waset.org/abstracts/198689/impact-of-anthropometric-parameters-and-course-of-osteogenesis-imperfecta-in-children-on-fgf23-levels" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/198689.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">2</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1</span> Molecular Docking and Synthesis of Nitrogen-Containing Bisphosphonates </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=S.%20Ghalem">S. Ghalem</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Mesmoudi"> M. Mesmoudi</a>, <a href="https://publications.waset.org/abstracts/search?q=I.%20Daoudand"> I. Daoudand</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Allali"> H. Allali</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The nitrogen-containing bisphosphonates (N-BPs) are well established as the treatments of choice for disorders of excessive bone resorption, myeloma and bone metastases, and osteoporosis. They inhibit farnesyl pyrophosphate synthase (FFPS), a key enzyme in the mevalonate pathway, resulting in inhibition of the prenylation of small GTP-binding proteins in osteoclasts and disruption of their cytoskeleton, adhesion/spreading, and invasion of cancer cells. A very few examples for synthesis of α-amino bisphosphonates based on several amino acids are known from the literature. In the present work, esters of aminoacid react with ketophsophonate (or their analog acid or acyl) to afford the desired products, α-iminophosphonates. The reaction of imine with dimethyl phosphate in the presence of catalytic amount of I2 give ester of α-aminobisphosphonate as sole product in good yield. Finally, we used computational docking methods to predict how several α-aminobisphosphonates bind to FPPS and how R and X influence. Pamidronate, β-aminobisphosphonate already marketed, was used as reference. These results are of interest since they represent a new and simple way to sythesize α-aminobisphosphonates with a free COOH group increased by R2 functionalisable and opening up the possibility of using the molecular docking to facilitate the design of other, novel FFPS inhibitors. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=drug%20research" title="drug research">drug research</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=%CE%B1-amino%20bisphosphonates" title=" α-amino bisphosphonates"> α-amino bisphosphonates</a>, <a href="https://publications.waset.org/abstracts/search?q=molecular%20docking" title=" molecular docking"> molecular docking</a> </p> <a href="https://publications.waset.org/abstracts/43154/molecular-docking-and-synthesis-of-nitrogen-containing-bisphosphonates" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/43154.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">275</span> </span> </div> </div> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2025 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>